Apontis Pharma AG
Alfred-Nobel-Str. 10
Monheim am Rhein 40789
Germany
49 2173 8955 4949
https://apontis-pharma.de
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 177
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Bruno Wohlschlegel | Chairman of Management Board | 180.96k | 無 | 1968 |
| Mr. Thomas Milz | Chief Product Officer & Deputy Chairman of Management Board | 324k | 無 | 無 |
| Mr. Thomas Zimmermann | Chief Financial Officer | 無 | 無 | 無 |
| Mr. Harald Weyand | Head of Marketing | 無 | 無 | 無 |
| Dr. Matthias Wendl | Head of Sales | 無 | 無 | 無 |
| Ms. Susanne Böhm | Head of HR | 無 | 無 | 無 |
| Dr. Olaf Randerath | Head of Medicine | 無 | 無 | 無 |
| Dr. Susanne Endreß | Head of QA, Drug Safety & Regulatory Affairs | 無 | 無 | 無 |
截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。
描述
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.
公司管治
截至 無 止，Apontis Pharma AG 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
